Fairfield, Bush & Co’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $295K | Sell |
2,117
-41
| -2% | -$5.74K | 0.16% | 98 |
|
|
2025
Q4 | $265K | Sell |
2,158
-268
| -11% | -$32.6K | 0.14% | 102 |
|
|
2025
Q3 | $269K | Hold |
2,426
| – | – | 0.14% | 101 |
|
|
2025
Q2 | $269K | Sell |
2,426
-50
| -2% | -$5.32K | 0.15% | 94 |
|
|
2025
Q1 | $277K | Buy |
+2,476
| New | +$255K | 0.18% | 91 |
|
|
2024
Q1 | – | Sell |
-126
| Closed | -$10.2K | – | 241 |
|
|
2023
Q4 | $10.2K | Buy |
+126
| New | +$9.8K | 0.01% | 305 |
|
|
2023
Q3 | – | Sell |
-126
| Closed | -$9.71K | – | 251 |
|
|
2023
Q2 | $9.71K | Buy |
+126
| New | +$10K | ﹤0.01% | 326 |
|
|
2022
Q3 | – | Sell |
-92
| Closed | -$6K | – | 239 |
|
|
2022
Q2 | $6K | Buy |
+92
| New | +$5.7K | ﹤0.01% | 337 |
|
|
2021
Q3 | – | Sell |
-5,769
| Closed | -$397K | – | 160 |
|
|
2021
Q2 | $397K | Sell |
5,769
-3,549
| -38% | -$237K | 0.11% | 119 |
|
|
2021
Q1 | $602K | Buy |
9,318
+730
| +9% | +$47.1K | 0.17% | 107 |
|
|
2020
Q4 | $500K | Sell |
8,588
-7,761
| -47% | -$468K | 0.15% | 104 |
|
|
2020
Q3 | $1.03M | Buy |
16,349
+400
| +3% | +$27.7K | 0.33% | 67 |
|
|
2020
Q2 | $1.23M | Buy |
15,949
+2,282
| +17% | +$175K | 0.44% | 52 |
|
|
2020
Q1 | $1.02M | Buy |
13,667
+7,950
| +139% | +$549K | 0.42% | 49 |
|
|
2019
Q4 | $371K | Sell |
5,717
-102
| -2% | -$6.64K | 0.14% | 110 |
|
|
2019
Q3 | $369K | Hold |
5,819
| – | – | 0.13% | 108 |
|
|
2019
Q2 | $393K | Buy |
5,819
+17
| +0.3% | +$1.12K | 0.13% | 107 |
|
|
2019
Q1 | $377K | Buy |
5,802
+400
| +7% | +$26.6K | 0.13% | 108 |
|
|
2018
Q4 | $338K | Hold |
5,402
| – | – | 0.12% | 113 |
|
|
2018
Q3 | $417K | Hold |
5,402
| – | – | 0.12% | 115 |
|
|
2018
Q2 | $383K | Buy |
5,402
+12
| +0.2% | +$847 | 0.11% | 117 |
|
|
2018
Q1 | $406K | Hold |
5,390
| – | – | 0.12% | 115 |
|
|
2017
Q4 | $386K | Sell |
5,390
-325
| -6% | -$24.7K | 0.11% | 118 |
|
|
2017
Q3 | $463K | Hold |
5,715
| – | – | 0.14% | 103 |
|
|
2017
Q2 | $405K | Hold |
5,715
| – | – | 0.13% | 107 |
|
|
2017
Q1 | $388K | Sell |
5,715
-740
| -11% | -$52K | 0.12% | 109 |
|
|
2016
Q4 | $462K | Sell |
6,455
-180
| -3% | -$13.4K | 0.15% | 102 |
|
|
2016
Q3 | $525K | Sell |
6,635
-590
| -8% | -$47.9K | 0.17% | 96 |
|
|
2016
Q2 | $603K | Buy |
7,225
+2,430
| +51% | +$216K | 0.21% | 75 |
|
|
2016
Q1 | $440K | Sell |
4,795
-1,250
| -21% | -$113K | 0.16% | 95 |
|
|
2015
Q4 | $612K | Buy |
6,045
+2,490
| +70% | +$259K | 0.21% | 77 |
|
|
2015
Q3 | $349K | Sell |
3,555
-1,135
| -24% | -$126K | 0.15% | 96 |
|
|
2015
Q2 | $549K | Buy |
4,690
+175
| +4% | +$19.1K | 0.17% | 101 |
|
|
2015
Q1 | $443K | Buy |
4,515
+200
| +5% | +$20.3K | 0.13% | 116 |
|
|
2014
Q4 | $407K | Buy |
+4,315
| New | +$446K | 0.12% | 124 |
|
Other funds holding GILD
VCM
VPM
Fairfield, Bush & Co's GILD Position: Q1 2026 in Review
Fairfield, Bush & Co reduced its Gilead Sciences (GILD) stake by 1.9% in Q1 2026, selling an estimated $5.74K and leaving 2,117 shares worth $295K. The position accounts for 0.16% of the portfolio, ranked #98.
Fairfield, Bush & Co first reported a position in GILD in Q4 2014 and has held it in 35 quarters since. The position peaked at $1.23M in Q2 2020. 2,311 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- Fairfield, Bush & Co held 2,117 shares of Gilead Sciences worth $295K as of Q1 2026.
- Fairfield, Bush & Co sold 41 Gilead Sciences shares in Q1 2026, an estimated $5.74K.
- Gilead Sciences made up 0.16% of Fairfield, Bush & Co's portfolio in Q1 2026, its #98 holding.
- Fairfield, Bush & Co first reported a position in Gilead Sciences in Q4 2014 and has held it in 35 quarters since.
- Fairfield, Bush & Co's Gilead Sciences position peaked at $1.23M in Q2 2020.
- 2,311 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on Fairfield, Bush & Co's 13F filing for Q1 2026, filed 12 May 2026.